SPOTLIGHT -
John Kuruvilla, MD, Discusses Toxicities Observed in the Phase 3 KEYNOTE-204 Study
The expert in hematology highlighted the toxicities reported in this trial and explained the differences observed between the 2 drugs studied.
John Kuruvilla, MD, on Next Steps for the Phase 3 KEYNOTE-204 Study
The expert in hematology discussed the next steps for the trial and what the goals are for the use of pembrolizumab in this patient population moving forward.
John Kuruvilla, MD, on the KEYNOTE-204 Study Findings
The study evaluated the use of pembrolizumab compared with brentuximab vedotin in patients with relapsed or refractory classic Hodgkin Lymphoma.
John Kuruvilla, MD, on Key Findings from the Phase 3 KEYNOTE-204 Trial
The expert in hematology suggested that these findings represent a clinically meaningful benefit for patients that received pembrolizumab in the study, compared to those who received brentuximab vedotin.
John Kuruvilla, MD, on the Implications of the Phase III KEYNOTE-204 Study
Results from the study indicated that pembrolizumab (Keytruda) was superior to brentuximab vedotin (Adcetris) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
